Only a few studies have been conducted on the virologic efficacy of this regimen, and they generally showed poor results.
Current WHO guidelines recommend four options for initial HIV treatment: tenofovir + 3TC + nevirapine, tenofovir/FTC + nevirapine, tenofovir + 3TC + efavirenz, and tenofovir/FTC/efavirenz. However, concerns have been raised about whether these four regimens are equally effective.
Investigators conducted a systematic review of all published or presented studies that involved at least one WHO-recommended first-line regimen. Of the 206 relevant publications identified, 34 met inclusion criteria.
Tenofovir + 3TC + nevirapine was found to be the least-studied regimen and also the one with the poorest results: Of the three studies available, two were prospective trials involving <100 patients. Both were terminated early because of high rates of vir…
Reviewing Authors
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)